Johnson & Johnson ROA 2010-2022 | JNJ

Current and historical return on assets (ROA) values for Johnson & Johnson (JNJ) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Johnson & Johnson ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-06-30 $18.37B $177.72B 10.24%
2022-03-31 $19.83B $178.36B 11.08%
2021-12-31 $20.88B $182.02B 11.76%
2021-09-30 $17.88B $179.23B 10.17%
2021-06-30 $17.77B $176.44B 10.23%
2021-03-31 $15.12B $172.56B 8.94%
2020-12-31 $14.71B $174.89B 8.93%
2020-09-30 $16.99B $170.69B 10.59%
2020-06-30 $15.19B $158.38B 9.69%
2020-03-31 $17.17B $155.02B 11.01%
2019-12-31 $15.12B $157.73B 9.78%
2019-09-30 $14.15B $155.52B 9.22%
2019-06-30 $16.33B $155.12B 10.64%
2019-03-31 $14.68B $150.03B 9.56%
2018-12-31 $15.30B $152.95B 9.86%
2018-09-30 $1.54B $155.70B 0.99%
2018-06-30 $1.37B $155.37B 0.88%
2018-03-31 $1.25B $156.63B 0.80%
2017-12-31 $1.30B $157.30B 0.85%
2017-09-30 $15.83B $155.66B 10.65%
2017-06-30 $16.34B $152.81B 11.28%
2017-03-31 $16.51B $144.92B 11.66%
2016-12-31 $16.54B $141.21B 11.86%
2016-09-30 $15.94B $140.37B 11.60%
2016-06-30 $15.03B $139.81B 11.08%
2016-03-31 $15.55B $136.23B 11.62%
2015-12-31 $15.41B $133.41B 11.69%
2015-09-30 $14.72B $133.27B 11.23%
2015-06-30 $16.11B $132.04B 12.32%
2015-03-31 $15.92B $128.59B 12.10%
2014-12-31 $16.32B $130.36B 12.30%
2014-09-30 $17.32B $132.10B 12.99%
2014-06-30 $15.55B $135.20B 11.78%
2014-03-31 $15.06B $133.33B 11.65%
2013-12-31 $13.83B $132.68B 10.94%
2013-09-30 $12.88B $126.93B 10.43%
2013-06-30 $12.87B $124.33B 10.59%
2013-03-31 $10.44B $121.54B 8.74%
2012-12-31 $10.85B $121.35B 9.19%
2012-09-30 $8.50B $118.95B 7.32%
2012-06-30 $8.74B $115.75B 7.64%
2012-03-31 $10.11B $116.19B 8.91%
2011-12-31 $9.67B $113.64B 8.68%
2011-09-30 $11.40B $111.82B 10.48%
2011-06-30 $11.61B $112.11B 11.02%
2011-03-31 $12.28B $108.15B 12.23%
2010-12-31 $13.33B $102.91B 13.79%
2010-09-30 $13.60B $98.25B 14.36%
2010-06-30 $13.53B $92.30B 14.54%
2010-03-31 $13.29B $93.44B 14.47%
2009-12-31 $12.27B $94.68B 13.64%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $435.655B $93.775B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $292.179B 37.05
AbbVie (ABBV) United States $249.673B 10.61
Pfizer (PFE) United States $245.989B 7.21
Merck (MRK) United States $218.318B 11.40
Novo Nordisk (NVO) Denmark $215.616B 28.44
Novartis AG (NVS) Switzerland $165.082B 12.17